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Objective: Coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently a pandemic.
Although pulmonary health has been the primary focus of studies during the
early days of COVID-19, development of a comprehensive understanding of
this emergent disease requires knowledge of all possible disease manifesta-
tions in affected patients. This Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)-compliant review focuses on cutaneous
manifestations reported in COVID-19 patients.
Approach: Literature review was conducted using the PubMed database to
examine various cutaneous manifestations related to the SARS-CoV-2 infec-
tion. Published articles (n = 56) related to search criteria from the onset of the
COVID-19 pandemic to June 30, 2020, were included. The primary literature
articles included in this study were mainly from France, Spain, Italy, and the
United Kingdom.
Results: Unique to many other symptoms of COVID-19, its cutaneous mani-
festations have been found in people of all age groups, including children. The
cutaneous manifestations of COVID-19 are varied and include maculopapular,
chilblain-like, urticarial, vesicular, livedoid, and petechial lesions. In addition,
rashes are common in multisystem inflammatory syndrome in children, a new
and serious health condition that shares symptoms with Kawasaki disease and
is likely related to COVID-19. In addition, personal protective equipment-
related skin wounds are of serious concern since broken cutaneous barriers
can create an opening for potential COVID-19 infections.
Innovation and Conclusion: As this virus continues to spread silently, mainly
through asymptomatic carriers, an accurate and rapid identification of these
cutaneous manifestations may be vital to early diagnosis and lead to possible
better prognosis in COVID-19 patients. This systematic review and photo atlas
provide a detailed analysis of the skin pathologies related to COVID-19. Study
of these cutaneous manifestations and their pathogenesis, as well their sig-
nificance in human health will help define COVID-19 in its entirety, which is a
prerequisite to its effective management.
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SCOPE AND SIGNIFICANCE
Cutaneous manifestations have been increas-
ingly reported in association with the coronavirus
disease 2019 (COVID-19) pandemic. Despite an
increase in relevance, much remains unknown
concerning the characterization, incidence, and
pathogenesis of these dermatological symptoms.
This Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)-compliant
systematic review provides a detailed analysis
on the changes in skin morphology related to
COVID-19 and discusses plausible underlying
molecular mechanisms. Furthermore, this review
discusses cutaneous complications associated
with personal protective equipment (PPE) and
their potentially serious consequences. Study of
these cutaneous manifestations and their path-
ogenesis, as well as their significance in hu-
man health will help define COVID-19 in its
entirety, which is a prerequisite to its effective
management.
TRANSLATIONAL RELEVANCE
This work is directly translationally relevant
because it reviews critical evidence primarily
originating from COVID-19 patients. Given that
the report is presented at the time when the pan-
demic is ongoing, it is expected that the content
will provide both health care providers as well as
researchers with critical insight helpful to improve
disease management. In addition, this article will
help construct novel experimental hypotheses for
future research.
CLINICAL RELEVANCE
COVID-19’s cutaneous symptoms appear in pa-
tients of all ages with differing levels of severity.
Currently, the importance of these symptoms re-
mains relatively unknown by many health care
personnel due to a shortage of literature reviews.
This review consolidates available data and sum-
marizes information of each skin manifestation, in-
cluding their incidence, susceptible age groups,
location of lesions, severity, and time of onset rela-
tive to other COVID-19 clinical symptoms. An in-
crease in awareness and identification of these
cutaneous manifestations by physicians may be vital
to an earlier and more accurate diagnosis, possibly
resulting in better prognosis in COVID-19 patients.
INTRODUCTION
COVID-19, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a re-
spiratory tract infection that has rapidly spread
worldwide since its first identification in Wuhan,
China, during December of 2019.1,2 The asymp-
tomatic transmission, high infection rate, and
high mortality rate among the elderly and im-
munocompromised associated with this disease
led the World Health Organization to declare it as
a pandemic in March 2020. As of early August
2020, in excess of 20 million cases of COVID-19
have been confirmed globally with more than
750,000 deaths reported in over 200 countries and
territories.
SARS-CoV-2 is a novel enveloped, positive-
sense, single-stranded RNA virus that is part of the
genus Betacoronavirus.1 Angiotensin-converting
enzyme 2 (ACE2) is a protein that functions as the
sole receptor for SARS-CoV-2 to invade cells and
cause infection in humans.3 Although this virus
primarily attacks the respiratory tract, ACE2 gene
expression has been discovered in several human
tissues, including gastrointestinal and skin tis-
sue.3 In a recent analysis of 31 Genotype-Tissue
Expression human tissue, Li et al.3 have found
that among human organs, small intestine, testis,
kidneys, heart, thyroid, and adipose tissue have
the highest ACE2 expression levels, while blood,
spleen, bone marrow, brain, blood vessels, and
muscle have the lowest ACE2 expression levels.
Other organs like lungs, colon, liver, bladder,
and adrenal glands have medium expression of
ACE2 in the human body.3 To investigate whether
skin was a potential target for SARS-CoV-2 infec-
tion, Xue et al.4 analyzed datasets available in
public domain (GEPIA2 and ARCHS4) to explore
ACE2 mRNA expression and ACE2-positive cell
composition in skin tissues. The expression of
ACE2 was significantly higher in keratinocytes
than other cellular compartments in skin tissues,
such as fibroblasts and melanocytes.4 This was
further validated through independent single-cell
RNA-seq data in which Xue et al.4 have found that
out of all ACE2-positive cells in skin, keratinocytes
account for 97.37% followed by sweat gland cells
that account for 2.63%. The widespread expression
of ACE2 suggests that this virus might be respon-
sible for infecting other human tissues alongside
the lungs, and could potentially result in additional
clinical manifestations.3,4
COVID-19 has a high infectivity rate, primarily
due to its spread through respiratory droplets.
After an incubation period of 1–14 days, common
clinical symptoms such as ‘‘fever, cough, fatigue,
sputum production, shortness of breath, sore
throat, and headache’’ begin to appear.1 In addition
to these common symptoms, novel symptoms such
52 SINGH ET AL.
as a variety of cutaneous manifestations have
been reported worldwide.5 Early data from China
reported skin symptoms were present in only 0.2%
of 1,099 confirmed COVID-19 cases.6 However,
data from Italy later revealed a higher percentage
with skin manifestations present in 20.4% of 88
positive COVID-19 patients.5 Despite differences
in prevalence, reports of cutaneous lesions have
become increasingly common in many age groups,
including children who were once thought to be
asymptomatic to the infection. Although not much
is known concerning the pathophysiologic mecha-
nisms of these cutaneous manifestations, their
identification may be vital to early diagnosis and
lead to possible better prognosis in COVID-19 pa-
tients. This systematic review provides a detailed
analysis on the changes in skin morphology related
to COVID-19 and the possible molecular mecha-
nisms and health significance underlying these
cutaneous manifestations.
METHODS
Literature review was conducted using the
PubMed database to examine various cutaneous
manifestations related to the SARS-CoV-2 infec-
tion. Published articles related to search criteria
from the onset of the COVID-19 pandemic to June
30, 2020, were included. Search strategy included
‘‘COVID-19,’’ ‘‘coronavirus,’’ or ‘‘SARS-CoV-2’’ in
combination with relevant terminology such as
‘‘skin,’’ ‘‘cutaneous,’’ ‘‘chilblain-like,’’ ‘‘ maculopap-
ular,’’ ‘‘urticarial,’’ ‘‘livedo,’’ ‘‘vesicular,’’ ‘‘petechiae,’’
and ‘‘multisystem inflammatory syndrome.’’ Cases
series including five or more patients were selected
for this review. Individual case reports were ex-
cluded from the table data; however, may have
been used during analysis of various skin rashes.
In total, 56 articles complied with search criteria
and were used for data collection (Fig. 1).
Two authors (H.S. and H.K.) worked indepen-
dently, searched, and scanned all abstracts and
titles in duplicate to identify articles relevant to
this study. When discrepancies occurred, a third
reviewer (K.S.) made the final judgment. Singh and
Kaur assessed eligibility from full-text articles,
with a similar process for potential disagreements
as described above. Data extraction from included
studies (i.e., published abstracts and articles) was
duplicated with a standardized extraction form.
The characteristics of the research (study design,
antiviral regimen, therapy duration, etc.), the out-
comes of interest mentioned above, and biased risk
assessment were extracted. The source of the data
presented in this review article was from published
papers available in public domain hence IRB ap-
proval was not needed.
RESULTS
Cutaneous manifestations associated with
COVID-19 infection are numerous and can vary
greatly when compared to one another. The six
central dermatological patterns of COVID-19 are
described as maculopapular/morbilliform, urticar-
ial, vesicular, chilblain like, petechiae/purpura,
and livedoid. These clinical findings can be further
classified as either inflammatory (maculopapular/
morbilliform, urticarial, and vesicular) or vascular
lesions (chilblain-like, petechiae/purpura, and li-
vedoid).7 Due to scientific need for appropriate
classification of these cutaneous manifestations, an
algorithm has been published to provide for easier
classification of the main COVID-19 skin findings
mentioned earlier.8 Finally, multisystem inflam-
matory syndrome in children (MIS-C), a novel ill-
ness thought to be related to COVID-19, can also
present with dermatological symptoms, although
clarification of their cutaneous classifications is
needed.
Maculopapular/morbilliform lesions
Maculopapular lesions are amongst the most
prevalent cutaneous manifestations seen through-
out the COVID-19 pandemic (Table 1) are maculo-
papular lesions. These lesions are frequently the
result of adverse drug reactions or viral infections.9
Maculopapular lesions occurring in children are
typically the result of viral infections, whereas drug
eruptions are usually the trigger for these lesions in
adults10 (Fig. 2).
A case series of 375 patients with skin lesions
associated with COVID-19 identified a 47% prev-
alence of maculopapular lesions.11 Prevalence of
these lesions has varied among studies with a
smaller number of cases, ranging from 5% to 70%.
Many of the maculopapular rashes reported were
observed in middle-aged or elderly patients11–14;
however, cases have appeared in younger adults.15
Anatomically, the majority of these lesions were
located on the trunk of the body.12,13,15–18 Despite a
large case series from Spain reporting simulta-
neous onset of many maculopapular lesions with
COVID-19’s systemic symptoms,11 other studies
had noticed a later onset in their smaller patient
populations.12–14,19 Studies with a later onset of
cutaneous manifestations reported average la-
tency times of 27.6 days and 27.85 days.12,13 Mean
duration of the exanthems ranged from 8.6 to
11.6 days.11–13 According to one case series, pruri-
tus was present in 56% of patients with maculo-
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papular lesions. Interestingly, the same study
suggested that maculopapular rashes are associ-
ated with greater severity of COVID-19 infections;
this was supported by a 2% mortality rate reported
in patients with these lesions.11 Histopathological
findings for these lesions are dependent on the time
of onset.14 Early-onset rashes are presented with
moderate epidermal spongiosis and perivascular
lymphocytic infiltrate with eosinophils in the der-
mal region.14 Contrastingly, histology of late-onset
lesions exhibited perivascular lymphocytic infil-
trate and histiocytes among collagen fibers. These
late-onset lesions are devoid of mucin deposits.14
Additional examination by Reymundo et al. re-
ported presence of mild superficial perivascular
lymphocytic infiltrate in skin biopsies.13
There have been a few theories discussed con-
cerning the molecular mechanisms of maculo-
papular lesions. Galván Casas et al. described
these lesions as unhelpful toward diagnosis due to
Figure 1. The PRISMA statement of this review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Source: Moher D, Liberati A,
Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. The PRISMA Group. PLoS Med 6:e1000097.
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Total population: 210 patients
Male age, mean:
57.44 – 17.259 years
Female age, mean:
58.80 – 15.918 years
123 male (58.6%), 87 female (41.4%)
Skin lesions: 52/210 (24%):
33 male (26.8%), 19 female (21.8%)
Maculopapular: 12/52 (23%)
SARS-CoV-2 PCR in total population,
PCR performed in 158 patients:
Positive: 88/158 (55.7%)
Negative: 70/158 (44.3%)




Classification of 52 patients with
skin lesions:
Erythematous scaly rash
(n = 17, 32.7%)
Maculopapular rash (n = 12, 23%)
Urticarial lesions (n = 7, 3.5%)
Petechial purpuric rash (n = 4, 7.7%)
Necrosis (n = 4, 7.7%)
Enanthema, aphthous stomatitis
(n = 3, 5.8%)
Vesicular rash (n = 3, 5.8%)
Pernio (n = 1, 1.9%)
Most maculopapular lesions
were located on trunk;
in one case, lesion was
present on the extremities.
Dalal
et al. (2020)27
Total population: 102 patients
Age, mean (SD): 39.30
years (SD 17.9)
95 male (93.1%), 7 female (6.9%)




Classification of 13 patients with
skin lesions:
Maculopapular rash (n = 3, 23.1%)
Urticarial lesions (n = 2, 15.4%)
Pruritis without specific
cutaneous signs
(n = 8, 69.2%)
Location of maculopapular
lesions:
Trunk (n = 3)





Total population: 277 patients
Age, mean (range): 27 years (2–98)
‘‘Half of patients were male’’
Skin lesions: 277/277 (100%)
Morbilliform: 25/277 (9%)
Age, median (range): 29 years (2–70)
10 male (48%), 11 female (52%)





Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)




(n = 25, 100%)
Face (n = 2, 8%)
Docampo-Simon
et al. (2020)35
Total population: 58 patients
Age, median (range): 14 years
(3 months–85 years)
29 male (50%), 29 female (50%)
Skin lesions: 58/58 (100%)
Maculopapular: 3/58 (5.17%)





Chilblain-like lesions (n = 42)
Purpuric (n = 3)
Maculopapular (n = 3)
Vesiculobullous (n = 3)
Eczematous (n = 3)
Paronychia (n = 2)
Ulcer (n = 1)
Desquamation (n = 1)
Location of ALL lesions:
Hands (n = 9, 15.5%)
Feet (n = 36, 62.1%)
Hands and Feet
(n = 13, 22.4%)
Galvan
et al. (2020)11
Total population: 375 patients
153 males (40.8%),
222 females (59.2%)
Skin lesions: 375/375 (100%)
Maculopapular: 176/375 (47%):
Age, mean (SD): 55.3 years (20.2)
78 male (44.3%), 98 female (55.7%)
Laboratory confirmation
of SARS-CoV-2











Livedo or necrosis (6%)
Perifollicular distribution
Extremities: dorsum of hands
Herrero-Moyano
et al. (2020)12
Total population: 1,177 patients
Skin lesions: 8/1,177 (0.7%)
Maculopapular: 8/8 (100%)
Age, mean (range): 72.2
years (51–88)
4 male (50%), 4 female (50%)







some with violaceous center;
one patient developed pustules
and desquamation
Location of morbilliform lesions:
Trunk (n = 7)
Flexures (n = 4)
Proximal extremities (n = 2)
Face (n = 2)
Generalized (n = 1)
Reymundo
et al. (2020)13
Total population: 18 patients









Location of morbilliform lesions:
Involvement of the
trunk (n = 7)
Proximal upper limb
involvement (n = 6)
Lower limb involvement (n = 1)
Rubio-Muniz
et al. (2020)14
Total population: 34 patients
Age, median (range):
54.5 years (31–66)
14 male (41%), 20 female (59%)




4 male (40%), 6 female (60%)
COVID-19 diagnosis (total population):
Positive PCR: 17/34 (50%)
Positive radiology: 8/24 (23.5%)
Negative PCR: 9/34 (26.5%)
COVID-19 diagnosis (maculopapular):
Positive PCR: 6/10 (60%)
Positive radiology: 3/10 (30%)
Negative PCR: 1/10 (10%)
Classification:
Maculopapular (n = 10)
Pseudo-chilblain (n = 9)
Targetoid lesions (n = 5)
Palpable purpura (n = 4, of which
2 cases are with vesicular lesions)
Acute urticaria (n = 3)
Vesicular (n = 2, these also have
palpable purpura)




COVID-19, Coronavirus Disease 2019; N/A, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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the potential cause of adverse drug reactions. This
is plausible as patients with these rashes had
more severe infections and therefore received
greater drug therapy.11 Potential drugs given
against COVID-19 such as Ribavirin, Colchicine,
intravenous immunoglobulin (IVIG) treatments,
Lopinavir, Ritonavir, and other antiretroviral
drugs are known to result in cutaneous side effects
similar to maculopapular and morbilliform ra-
shes.20 However, maculopapular eruptions have
been observed in case series with no new medica-
tions taken, suggesting that these lesions may not
solely be drug related.13 Finally, Herrero-Moyano
et al. proposed a hypothesis that a cytokine storm
produced by a hyperactive immune system could
be the instigator behind these rashes after ob-
serving late-onset maculopapular eruptions.12
Other significant hypotheses about the potential
causes of maculopapular lesions have been pro-
vided in Table 9.
Urticarial lesions
In addition to maculopapular rash, urticarial
lesions have also been noted in several COVID-19
case series. These lesions typically present as hives
or angioedema and can be characterized as an er-
ythematous slightly raised papular rash followed
by intense pruritic sensations.21 Although consid-
ered one of COVID-19’s most frequent cutaneous
manifestations, urticarial lesions have been a rel-
atively common dermatological condition even be-
fore the pandemic. Acute urticaria, defined as a
self-limiting lesion lasting less than 6 weeks, has
been reported to affect 20% of the general popula-
tion.22 Meanwhile, chronic urticaria, described as a
recurring lesion present for greater than 6 weeks,
Figure 2. Examples of maculopapular rash seen in COVID-19-positive patients. (A) Maculopapular lesions, a few of which present with a perifollicular
distribution, located on the thigh of patient. (B, C) Eleven-year-old child with COVID-19 presenting with pruritis and maculopapular lesions located on her face
and shoulder. Duration of lesions was 5 days. (D, E) Seventeen-year-old adolescent with COVID-19 presenting with a maculopapular rash and mild pruritis only
after receiving HCQ treatment, suggesting a drug-induced exanthema. (F) Nonspecific maculopapular rash located on the trunk of recovering COVID-19
patient. (G) Maculopapular rash appearing on posterior trunk of a confirmed COVID-19 patient. (H) Maculopapular lesions described as small plaques after
fusion of lesions. COVID-19, Coronavirus Disease 2019. Reproduced with permission from John Wiley and sons (A–G); Wolters Kluwer Health, Inc. (H). The
following original reports are credited: Galván Casas et al.11; Duramaz et al.19; Rubio-Muniz et al.14; Gianotti et al.18
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appears to affect 5% of the general population.22
Common triggers include viral/bacterial/parasitic
infections, environmental exposures, and immuno-
globulin E-mediated allergic reactions in response
to medications, food, or biting/stinging insects.22
Urticarial lesions typically resolve after removal
of the offending agent; however, in severe cases,
the use of antihistamines and steroids has been
implemented for symptomatic relief (Fig. 3).
Acute urticarial lesions have been discussed in
several COVID-19 studies11,14,16,20,23–26 (Table 2).
Prevalence of these lesions among other skin
Figure 3. Examples of urticarial rash seen during the COVID-19 pandemic. (A) Urticarial lesions dispersed along buttocks and proximal lower extremity
(thigh). (B) Urticarial rash, similar to hives, appearing on patient’s neck and chest. (C, D) Thirty-nine-year-old nurse presenting with generalized pruritic
urticarial rash 2 days before the onset of pyrexia, chills, myalgia, and headache. Lesions were located on her thigh (C) and back (D). (E) Generalized pruritic
urticaria present on elderly man with COVID-19 infection. (F) Thirty-two-year-old female presenting with a dispersed urticarial rash on her face, trunk, and
lower limbs. Lesion onset was 6 days after first COVID-19 clinical symptoms and lesion duration was 5 days. (G) Staff nurse presenting with widespread
urticarial eruption involving her face, arms, torso, legs, and loins. Lesion onset was before presentation of COVID-19 clinical symptoms. (H) ‘‘Urticarial pattern
with mild edema, perivascular inflammation, and dilated vessels in the upper dermis. Inset: vessels filled with neutrophils and mixed perivascular inflammation.’’
Reproduced with permission from John Wiley and sons (A–F, H); BMJ Publishing Group Ltd. (G). The following original reports are credited Galván Casas
et al.11; Marzano et al.50; van Damme et al.23; Najafzadeh et al.24; Cabrera-Hernández et al.25; Hassan.26
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Total population: 210 patients
Male age, mean:
57.44 – 17.259 years
Female age, mean:
58.80 – 15.918 years
123 male (58.6%), 87 female (41.4%)
Skin lesions: 52/210 (24%):
33 male (26.8%), 19 female (21.8%)
Urticaria: 7/52 (13.5%)
SARS-CoV-2 PCR in total population,
PCR performed in 158 patients:
Positive: 88/158 (55.7%)
Negative: 70/158 (44.3%)




Classification of skin lesions:
Erythematous scaly rash (n = 17, 32.7%)
Maculopapular rash (n = 12, 23%)
Urticarial lesions (n = 7, 3.5%)
Petechial purpuric rash (n = 4, 7.7%)
Necrosis (n = 4, 7.7%)
Enanthema, aphthous stomatitis (n = 3, 5.8%)
Vesicular rash (n = 3, 5.8%)






Total population: 14 patients
Age/gender NR
Skin lesions: 14/14 (100%)
Urticaria: 1/14 (7.1%)
SARS-CoV-2 PCR in 14 patients:
Positive: 14/14 (100%)
Inflammatory lesions: 7/14
Exanthema (n = 4)
Chicken pox-like virus (n = 2)
Cold urticaria (n = 1)
Vascular lesions: 7/14
Violaceous macules with ‘‘porcelain-like’’
appearance (n = 1)
Livedo (n = 1)
Non-necrotic purpura (n = 1)
Necrotic purpura (n = 1)
Chilblain appearance with Raynaud’s
phenomenon (n = 1)
Chilblain (n = 1)




Total population: 102 patients
Age, mean (SD): 39.30 years (SD 17.9)
95 male (93.1%), 7 female (6.9%)
Skin lesions: 13/102 (12.7%)
Urticaria: 2/13 (15.4%)
SARS-CoV-2 PCR in 102 patients:
Positive: 102/102 (100%)
Classification of skin lesions:
Maculopapular rash (n = 3, 23.1%)
Urticarial lesions (n = 2, 15.4%)
Pruritis without specific cutaneous signs
(n = 8, 69.2%)
Location of urticarial lesions:
Trunk (n = 2)
De Giorgi
et al. (2020)17
Total population: 678 patients
Skin lesions: 53/678 (7.8%)
Age, mean (range): 55.9 years (28–69)
32 male (60%), 21 female (40%)
Urticaria: 14/53 (26%)
SARS-CoV-2 PCR in 678 patients:
Positive: 678/678 (100%)
Inflammatory manifestations:
Erythematous rash (n = 37, 70%)
Diffuse urticaria (n = 14, 26%)









Total population: 277 patients
Age, mean (range): 27 years (2–98)
‘‘Half of patients were male’’
Skin lesions: 277/277 (100%)
Urticaria: 26/277 (9%)
Age, median (range): 3 years (2–23)
13 male (56.5%), 10 female (43.5%)
SARS-CoV-2 PCR in 34 patients (12%):
Positive: 25/34 (73.5%)
Negative: 9/34 (26.5%)
Classification of skin lesions:
Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)
Other types of lesions (n = 41, 15%)
Location of urticarial lesions:
Trunk and limbs
(n = 24, 92%)
Face (n = 2, 8%)
Galvan
et al. (2020)11
Total population: 375 patients
153 males (40.8%),
222 females (59.2%)
Skin lesions: 375/375 (100%)
Urticaria: 73/375 (19%):
Age, mean (SD) = 48.7 years (19.9)
26 male (35.6%), 47 female (64.3%)
Laboratory confirmation of SARS-CoV-2











Livedo or necrosis (6%)
Most urticarial lesions were
dispersed or located on the
trunk. A few cases were
located on the palms.
Recalcati
et al. (2020)5
Total population: 88 patients
Age/gender—N/A





Erythematous rash (n = 14)
Widespread urticaria (n = 3)
Chicken pox-like vesicles (n = 1)
Trunk was the primary
location for all lesions.
Rubio-Muniz
et al. (2020)14
Total population: 34 patients
Age, median (range):
54.5 years (31–66)
14 male (41%), 20 female (59%)




1 male (25%), 3 female (75%)
COVID-19 diagnosis (total population):
Positive PCR: 17/34 (50%)
Positive radiology: 8/24 (23.5%)
Negative PCR: 9/34 (26.5%)
COVID-19 diagnosis (Urticarial):
Positive PCR: 2/4 (50%)
Positive radiology: 1/4 (25%)
Negative PCR: 1/4 (25%)
Classification:
Maculopapular (n = 10)
Pseudo-chilblain (n = 9)
Targetoid lesions (n = 5)
Palpable purpura (n = 4, of which 2 cases
are with vesicular lesions)
Acute urticaria (n = 3)
Vesicular (n = 2, these also
have palpable purpura)
Remaining 3 cases include livedo reticularis,




Total population: 20 patients
Age, median: 51 years
17 male (85%), 3 female (15%)
Skin lesions: 18/20 (90%)
Urticaria: 2/18 (11.1%)
Confirmed: 18/18 (41%) Classification:
Exanthematic rashes (n = 9)
Acral vasculitis eruptions (n = 6)
Polymorpho-like urticaria (n = 2)
Varicellifom eruption (n = 1)
Figure 1:
Polymorpho-like urticaria
located on the left hand
NR, not reported.
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manifestations has varied from 7% to 40% in
smaller case series. These lesions were common
among middle-aged patients11,14; however, a ret-
rospective study conducted in France reported a
median age of 3 years of age among 26 patients
with urticarial lesions.15 Many of these lesions
were distributed on the trunk or limbs.11,15,27 In
some cases, the rash was generalized across the
entire body or localized to the face.15,16 According to
the largest case series of urticarial lesions, onset is
thought to occur at the same time as other systemic
symptoms of COVID-19 with an average duration
of 6.8 days.11 However, it should be noted that in
a few instances, the onset of urticaria has mani-
fested before COVID-19’s systemic symptoms.11,28
Galván Casas et al. reported pruritus in 92% of
patients with urticarial lesions and associated
these lesions with a more severe COVID-19 infec-
tion.11 Histopathological examination for urticar-
ial lesions has been sparse; however, the results in
one case of urticariform rash present in a 32-year-
old woman displayed the presence of perivascular
infiltrate of lymphocytes, with few eosinophils and
upper dermal edema.29
Due to many cases of urticaria having an asso-
ciation with therapy, possible etiology of urticarial
lesions could involve drug-induced exanthema.11
Urticaria has been described as a cutaneous side
effect in many potential anti-COVID-19 drugs such
as chloroquine, hydroxychloroquine, lopinavir/
ritonavir, nitazoxanide, corticosteroids, baricitinib,
IVIG treatments, and checkpoint inhibitors.20 In
addition to adverse drug effects, another possible
pathophysiological mechanism leading to urticaria
could be overactivity of the immune system, resulting
in a potential ‘‘cytokine storm’’ involving the skin.30
Interestingly, cases of delayed pressure urticaria
have also been reported, although they are thought to
be a result of vertical pressure caused by PPE.31
Finally, a direct cutaneous effect by the SARS-
CoV-2 virus is always a possibility, considering
viral infections have sometimes been implicated as
the primary agent in urticarial cases in the past.
On account of the extreme variability in etiology of
urticarial skin lesions, these lesions are thought to
be a potentially inaccurate marker for diagnosis or
verification of COVID.11 Other significant hypoth-
eses about the potential causes of urticarial lesions
have been provided in Table 9.
Chilblain-like lesions (COVID toes)
Chilblain lesions, also referred to as pernio, are
characterized as a localized inflammatory skin
disorder, thought to be induced by exposure to
cold temperatures or damp humid environments
resulting in swelling and discoloration of the ex-
tremities (Fig. 4). The increased incidence of
pernio/acral-like or chilblain-like lesions, coupled
with the temporal association with viral symptoms,
has led to the colloquialization ‘‘COVID toes.’’ The
term comes from the cutaneous description in
which the skin involving their toes presents as er-
ythematous or violaceous lesions. Although some
cases are idiopathic, previous literature supports
chilblain association with autoimmune diseases
such as lupus.32 In some cases, the rash is seen with
the Raynaud’s phenomenon in which a trigger (cold
exposure or emotional stress) leads to skin discol-
orations of extremities through vasoconstriction.33
A retrospective review conducted by Cappel
et al. reported additional potential associations
with hematologic disease as well as hyperviscosity
syndrome. The rash is typically located on distal
acral extremities such as fingers and/or toes.32
Per UpToDate, the rash typically presents as
‘‘erythematous-violaceous papules, macules, or
nodules (UpToDate).’’ The pathogenesis behind
chilblains is not entirely understood. One sus-
pected mechanism revolves around cold-induced
vasoconstriction and vasospasm leading to hypox-
emia and inflammation. Other theories suggest
hyperviscosity or autoantibody-induced endothe-
lial damage (UpToDate). Treatment modalities
include heating, nonsteroidal anti-inflammatory
drugs (NSAIDs), topical steroids, and vasodilators.32
Lesions similar to chilblains, labeled as chilblain
like or pernio like, have rapidly become the most fa-
miliar of COVID-19’s cutaneous manifestations, in
part, due to the numerous studies published con-
cerning them (Table 3). The prevalence of these le-
sions varied considerably between studies. An
international case series consisting of 505 patients
with dermatological conditions reported pernio-like
lesions present in 63%.34 Among other studies, the
prevalence of chilblain-like lesions fluctuated from
14.3% to 72%.11,15,34–36 These vascular lesions were
commonly identified among adolescents and
young adults.11,15,34,35,37–43 Anatomical locations
of chilblain-like lesions were consistent between
studies with feet and hands being affected the most
often. On the hands and feet, the acral lesions would
typically localize on the fingers and toes, respectively.
The onset of chilblain-like lesions was almost
always after the onset of COVID-19’s systemic
symptoms and they normally lasted for about a
week or two on average. In one case series,
chilblain-like lesions were the only symptom in
55% of cases.34 Dermatological symptoms com-
monly associated with chilblain-like lesions were
pain and pruritus.11,34,35,37,38 Many of the patients
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presenting with pernio-like lesions were young and
healthy. These rashes were typically associated
with relatively mild COVID-19 infections.34 His-
topathological examination performed by Rubio-
Muniz et al. showed different patterns. In many of
the pseudo-chilblain cases, the histology displayed
focal vacuolar degeneration of the basal layer.
Regenerative changes were also observed in the
epidermis along with perivascular lymphocytic
cuffs in the dermal regions. Histology conducted in
another sample discovered presence of perivas-
cular neutrophilic cuffs with clear inflamed endo-
thelium and regions of epidermal necrosis.14
The exact mechanism of chilblain-like lesions is
not fully known as its presentation is unrelated to
cold exposure. Bouaziz et al. hypothesized patho-
physiology behind chilblain could involve ‘‘immune
dysregulation, vasculitis, vessel thrombosis, or
neoangiogensis.44’’ It also noted previous cases
with acro-ischemia and disseminated intravascu-
Figure 4. Examples of chilblain-like rash seen during the COVID-19 pandemic. (A) Acral chilblain-like lesions located on toes of patient. (B) Acral chilblain-
like lesions located on fingers of patient. (C) Pseudo-chilblain lesions present on the fingers of pediatric patient with no prior history of chilblains. (D) Acral
chilblain-like lesions located on toes of patient. (E) Chilblain-like lesions acrally located on toes of pediatric patient. (F, G) Lesions clinically similar to
chilblains, acrally located on toes of child during COVID-19 pandemic. (H) Chilblain-like lesions located on the heel of an adolescent. (I) Chilblain-like acral
lesion present on toes of patient from Italy. Examples of chilblain-like rash seen during the COVID-19 pandemic. (J) Acral pseudo-chilblains are seen on the
toes of a patient. (K) Acral pernio-like lesions affecting the toes of patient. (L) Pernio-like lesions affecting the distal extremity of patient. (M) Acral chilblain-
like lesions located on toes of an adolescent patient. (N) Pseudo-chilblain lesions described as erythemato-purpuric macules appeared on patient’s heel. (O)
‘‘Dense, superficial, and deep angiocentric and eccrinotropic lymphocytic infiltrate (H&E stain, 10 · ).’’ (P) ‘‘Papillary dermal edema, vacuolar degeneration of
the basal layer and lymphocytic exocytosis. Endothelia of small vessels appear swollen (H&E stain, 20 · ).’’ (Q) ‘‘Intense lymphocytic vascular reaction in
dermal vessels (H&E stain, 40 · ).’’ (R) ‘‘Red cell extravasation and focal thrombosis (arrow) in papillary dermis capillaries (H&E stain, 100 · ).’’ H&E, hematoxylin
and eosin. Reproduced with permission from John Wiley and sons (A–R). The following original reports are credited: Galván Casas et al.11; Garcia-Lara et al.41;
Andina et al.37; Wollina et al.43; Marzano et al.50; Gaspari et al.42; Rubio-Muniz et al.14
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Total population: 22 patients
Age, median (range):
12 years (6–17)
13 male (59%), 9 female (41%)
Skin lesions: 22/22 (100%)
Chilblain like: 22/22
SARS-CoV-2 PCR






macules; swollen toes with dusky
violaceous discoloration and less
frequently, dark ischemic areas
with superifical blisters
Feet affected in all cases,
toes most common.
(n = 22)
Lesions on fingers (n = 3)
Bouaziz
et al. (2020)44
Total population: 14 patients
Age/gender NR
Skin lesions: 14/14 (100%)
Chilblain like: 2/14 (14.3%)
SARS-CoV-2 PCR:
Positive: 14/14 (100%)
Inflammatory lesions = 7/14:
Exanthema (n = 4)
Chicken pox-like virus (n = 2)
Cold urticaria (n = 1)
Vascular lesions = 7/14:
Violaceous macules with
‘‘porcelain-like’’ appearance (n = 1)
Livedo (n = 1)
Non-necrotic purpura (n = 1)
Necrotic purpura (n = 1)
Chilblain appearance with Raynaud’s
phenomenon (n = 1)
Chilblain (n = 1)




Total population: 30 patients
Age, median (range) =
11 years (2–17)
17 male (56.7%), 13 female (43.3%)
Skin lesions: 30/30 (100%)
Chilblain like: 30/30
SARS-CoV-2 PCR




patches or slightly infiltrated plaques.
Location of lesions:
Feet (n = 26)
Ankles (n = 2)
Hands (n = 4)
Of 4 patients with hand




Total population: 277 patients
Age, mean (range): 27 years (2–98)
‘‘Half of patients were male’’
Skin lesions: 277/277 (100%)








Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)
Other types of lesions (n = 41, 15%)
Chilblain like: 106/142 acral lesions
Location of 34 acral lesions:
Hands (n = 23, 68%)
Face (n = 18, 53%)
Docampo-Simon
et al. (2020)35
Total population: 58 patients
Age, median (range): 14 years
(3 months–85 years)
29 male (50%), 29 female (50%)
Skin lesions: 58/58 (100%)
Chilblain like: 42/58 (72.4%)
SARS-CoV-2 PCR




Chilblain-like lesions (n = 42)
Purpuric (n = 3)
Maculopapular (n = 3)
Vesiculobullous (n = 3)
Eczematous (n = 3)
Paronychia (n = 2)
Ulcer (n = 1)
Desquamation (n = 1)
Location of ALL lesions:
Hands (n = 9, 15.5%)
Feet (n = 36, 62.1%)
Hands and Feet
(n = 13, 22.4%)
Duong
et al. (2020)36
Total population: 295 patients
Age/gender NR
Skin lesions: 295/295 (100%)
Chilblain like: 146/295 (49.5%)
N/A Classification:
Chilblain-like lesions (n = 146),
Other manifestations such as urticaria,
rash, chicken pox like, or pityriasis




Total population: 19 patients
Age, mean (range):
14 years (11–17)





Swelling, erythema, purpuric macules




to distal toes. In addition
to toes, 9 patients also
had lesions on soles and
heel. Minority of patients
had only hand lesions.
(continued)
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lar coagulation (DIC) from initial reports from
Wuhan, China. The three main hypotheses of the
article were confounding factors, postviral immune
response, or immune antiviral response.44 In re-
gard to a hypercoagulable state, one of the studies
reported the presence of microthrombi.39 Recent
studies have not been able to associate chilblain-
like lesions with positive COVID-19 infections;
therefore; these lesions should not be considered an
accurate indicator for diagnosis of COVID-19.45,46














Total population: 346 patients















Chilblain like (n = 95, 72%)
Erythema multiforme like (n = 37, 28%)
Location of lesions:
Hands (n = 33, 34.7%)
Feet (n = 73, 76.8%)
Distribution:
Digital (n = 87, 91.6%)
Dorsal (n = 23, 24.2%)
Ventral (n = 3, 3.2%)
Heels/wrists
(n = 12, 12.6%)
Freeman
et al. (2020)34
Total population: 505 patients
Skin lesions: 505/505 (100%)
Chilblain like: 318/505 (63%)
Age, mean (IQR): 25 years (17–38)





Acral desquamation in 4.4%
Location of lesions:
Only on feet (84%)





Total population: 375 patients
153 males (40.8%),
222 females (59.2%)
Skin lesions: 375/375 (100%)
Chilblain like: 71/375 (19%)
Age, mean (SD): 32.5 years (21.5)
23 male (32%), 48 female (68%)
Laboratory confirmation
of SARS-CoV-2
















Total population: 27 patients
Age, mean: 14.4 years
18 male (66%), 9 female (34%)
Skin lesions: 27/27 (100%)
Chilblain like: 25/27 (92.6%)
SARS-CoV-2 tests:
PCR negative (n = 2)
IgM negative (n = 9)
IgA negative (n = 9)
IgG negative (n = 9)
Classification:
Chilblain-like lesions (n = 25, 92.6%)
Erythema multiforme-like rash
(n = 2, 7.4%)
Location of lesions:
Only on feet (74%)





Total population: 20 patients
Age, median: 51 years
17 male (85%), 3 female (15%)
Skin lesions: 18/20 (90%)
Chilblain like: 6/18 (33.3%)
Confirmed: 18/18 Classification:
Exanthematic rashes (n = 9, 50%)
Acral vasculitis eruptions (n = 6, 33.3%)
Polymorpho-like urticaria (n = 2, 11.1%)





Total population: 14 patients
Age, mean (range): 14.4 years
(13–18), n = 11
Age, mean (range): 29 years
(23–39), n = 3
6 male (42.9%), 8 female (57.1%)
Skin lesions = 14/14 (100%)




Pernio-like lesions (n = 14)
Erythemato-papular targetoid
lesions (n = 2)
Description:
Acral eruption of erythemato-violaceous
papules and macules
Location of lesions:
Feet (n = 8)
Hands (n = 4)
Both hands and
feet (n = 2)
Rubio-Muniz
et al. (2020)14
Total population: 34 patients
Age, median (range): 54.5
years (31–66)
14 male (41%), 20 female (59%)
Skin lesions: 34/34 (100%)
Chilblain like: 9/34 (26.5%)
COVID-19 diagnosis (total population):
Positive PCR: 17/34 (50%)
Positive radiology: 8/24 (23.5%)
Negative PCR: 9/34 (26.5%)
COVID-19 diagnosis (pseudo-chilblain:
9 cases with livedo: 1 case):
Positive PCR: 2/10 (20%)
Positive radiology: 2/10 (20%)
Negative PCR: 6/10 (60%)
Classification:
Maculopapular (n = 10)
Pseudo-chilblain (n = 9)
Targetoid lesions (n = 5)
Palpable purpura (n = 4, of which 2 cases
are with vesicular lesions)
Acute urticaria (n = 3)
Vesicular (n = 2, these also have
palpable purpura)




IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IQR, interquartile range.
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Other significant hypotheses about the potential
causes of chilblain-like lesions have been provided
in Table 9.
Vesicular lesions
Vesicular is a descriptive term used to charac-
terize lesions that are clear fluid-filled sacs under
the epidermal layer. These lesions are commonly
referred to as blisters and tend to be less than 1 cm
in diameter, with many often appearing in clusters.
Most common causes are heat, contact dermatitis,
medications, autoimmune, or infectious (bacterial
or viral). Examples of viral infections that display
vesicular lesions include varicella-zoster, herpes
simplex, coxsackievirus, and echovirus infections.47
The prevalence of vesicular lesions among
COVID-19 patients with cutaneous manifestations
is not very common when compared to the lesions
mentioned earlier (Fig. 5). Various studies have
reported percentages ranging from 3.77% to 15%.
Vesicular lesions typically appear in middle-aged
patients11,15,48–50 (Table 4). The trunk of the body
was the most common location for this type of
rash; however, a fair number of these lesions were
also identified on the extremities.11,15,16,48–50 A
prospective study conducted by Fernandez-Nieto
et al. was able to further characterize vesicular
rash. Among 22 patients with vesicular lesions,
75% of them presented with a diffuse pattern of
polymorphic lesions and 25% displayed a localized
pattern of monomorphic lesions on the trunk.48
Other cases have also identified monomorphic
vesicles located on the trunk.11,16 The time of onset
of cutaneous manifestations relative to other
COVID-19 symptoms varied between the few stud-
ies reported.
A study from Spain found the majority of vesic-
ular lesions to occur at the same time as other sys-
temic symptoms,11 while two studies from Italy
reported most of their lesions appearing after
COVID-19 symptoms.48–50 The studies with later
onset of cutaneous manifestations had median la-
tency times of 3 days and 14 days.48–50 Despite dif-
ferences in rash onset, the studies did report a few
cases of vesicular lesions appearing before COVID-
19 symptoms. Duration of rash in the Spanish study
was 8.4 days on average.11 The two Italian studies
reported median duration of rash being 8 and
10 days.48,49 Prevalence of additional pruritic
symptoms among patients with vesicular lesions
fluctuated between 40.9% and 83.3% depending on
which study.11,48–50 Vesicular lesions are thought to
be associated with intermediate severity of COVID-
19.11,48 Histopathological examination was per-
formed in two studies and both described their
findings as being consistent with known viral in-
fections.48,49 In the first study, the skin biopsies of
two cases revealed presence of intraepidermal ves-
icles associated with mild acantolisis and ballooned
keratinocytes.48 Second study conducted skin biop-
sies in seven patients with histological examination
showing ‘‘basket-wave hyperkeratosis; slightly
atrophic epidermis; and vacuolar degeneration of
the basal layer with multinucleate, hyperchromatic
keratinocytes and dyskeratotic cells.’’49
There are a few theories regarding the patho-
physiologic mechanisms involved with vesicu-
lar lesions. Criado et al. mentioned that vesicular
eruption could be a result of immune system over-
activity causing a potential ‘‘cytokine storm’’ in-
volving the skin.30 The same study hypothesized a
direct cytopathic effect of SARS-CoV-2 on endo-
thelium dermal vessels could produce vesicular
lesions.30 Unlike maculopapular and urticarial le-
sions, vesicular lesions associated with COVID-19
are thought to be etiologically unrelated to antivi-
ral drugs or other COVID-19 treatments.48 Finally,
vesicular lesions have been described as ‘‘specific
cutaneous manifestations’’ of COVID-19; therefore,
their identification could potentially be useful for
diagnosis. Other significant hypotheses about the
potential causes of vesicular lesions have been
provided in Table 9.
Petechiae/purpura lesions
Petechiae are typically described as being small
nonblanching spots that are less than 2 mm in di-
ameter.51,52 These miniature lesions are charac-
terized as nonblanching due to them not vanishing
after brief pressure is applied to the skin manifes-
tation area. If the nonblanching lesions are greater
than 2 mm in diameter, they are labeled as pur-
pura. These subdermal hemorrhages have many
pathophysiological causes, including ‘‘thrombocy-
topenia, platelet dysfunction, disorders of coagu-
lation, and loss of vascular integrity.51’’ Petechial
rashes are associated with some viral infections,
including enterovirus, parvovirus B19, and dengue
virus.51
Petechiae/purpura rashes are among the less
commonly described cutaneous manifestations in
association with COVID-19 (Fig. 6). A retrospective
study from France consisting of 277 patients with
skin lesions reported petechial patterns present in
only 3% of patients (Table 5). The lesions were lo-
cated diffusely, acral, or on limbs.15 Another study
involving petechial purpuric rash noticed that the
majority of cases were petechiae located on distal
extremities.16 Two case series with a small number
of petechiae/purpuric lesions reported their onset
CUTANEOUS MANIFESTATIONS OF COVID-19 63
to be after COVID-19 symptoms.14,53 De Giorgi
et al. stated that diffuse petechiae and generalized
palpable purpura usually appeared in cases with a
greater severity of infection.17 This statement was
supported through a case series conducted in Spain
claiming that palpable purpuric lesions, present in
4 of 34 cases (11.8%), were more frequent in middle-
aged patients recovering from severe COVID-19
infections. Interestingly, of the four patients pre-
senting with palpable purpuric lesions, two of them
additionally exhibited atypical polymorphic papu-
lovesicular eruptions, while a third patient also
displayed an urticarial exanthem.14 A rare case of
necrotic purpura was reported among 2 purpura
Figure 5. Examples of vesicular rash seen during the COVID-19 pandemic. (A) Vesicular lesions, characterized as monomorphic, dispersed along patient’s
back. (B) Polymorphic vesicular lesions diffusely affecting patient’s entire trunk and upper/lower extremities. (C) Vesicular lesions scattered or clustered along
patient’s trunk. (D) Maculopapular lesions disseminated along patient’s trunk with additional vesicular lesions located on distal upper extremities (hands). (E)
Vesicular rash localized to patient’s anterior trunk with lesions appearing as monomorphic. (F) Patient’s palmar surfaces exhibiting vesicles. (G) Dispersed
vesicular rash appearing on the anterior trunk of a patient. (H) Patient presented with atypical papulovesicular eruptions, in addition to the purpuric lesions. (I)
Vesicular rash, similar in appearance to chicken pox, located along patient’s anterior trunk. (J) ‘‘Histological examination showing an intraepidermal vesicle
containing scattered multinucleated and ballooned keratinocytes, with mild acantolisis.’’ (K) ‘‘A deeper section of the vesicle reveals more extensive damage,
with epidermal detachment and confluent keratinocytic necrosis. The vesicle contains fibrinoid material with acute inflammation.’’ Reproduced with permission
from John Wiley and sons (A–H, J–K); Wolters Kluwer Health, Inc. (I). The following original reports are credited: Galván Casas et al.11; Fernandez-Nieto
et al.48; Marzano et al.50; Rubio-Muniz et al.14; Gianotti et al.18
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Total population: 210 patients
Male age, mean:
57.44 – 17.259 years
Female age, mean:
58.80 – 15.918 years
123 male (58.6%),
87 female (41.4%)




SARS-CoV-2 PCR in total population,
PCR performed in 158 patients:
Positive: 88/158 (55.7%)
Negative: 70/158 (44.3%)




Classification of 52 patients with skin lesions:
Erythematous scaly rash (n = 17, 32.7%)
Maculopapular rash (n = 12, 23%)
Urticarial lesions (n = 7, 3.5%)
Petechial purpuric rash (n = 4, 7.7%)
Necrosis (n = 4, 7.7%)
Enanthema, aphthous stomatitis (n = 3, 5.8%)
Vesicular rash (n = 3, 5.8%)
Pernio (n = 1, 1.9%)
Location of vesicular lesions:
A couple of them were
‘‘unilateral and monomorphic




Total population: 14 patients
Age/gender NR
Skin lesions: 14/14 (100%)
Vesicular: 2/14 (14.3%)
SARS-CoV-2 PCR in 14 patients:
Positive: 14/14 (100%)
Inflammatory lesions: 7/14
Exanthema (n = 4)
Chicken pox-like virus (n = 2)
Cold urticaria (n = 1)
Vascular lesions: 7/14
Violaceous macules with ‘‘porcelain-like’’
appearance (n = 1)
Livedo (n = 1)
Non-necrotic purpura (n = 1)
Necrotic purpura (n = 1)
Chilblain appearance with Raynaud’s
phenomenon (n = 1)
Chilblain (n = 1)




Total population: 678 patients
Skin lesions: 53/678 (7.8%)
Age, mean (range):
55.9 years (28–69)
32 male (60%), 21 female (40%)
Vesicular: 2/53 (4%)
SARS-CoV-2 PCR in 678 patients:
Positive: 678/678 (100%)
Inflammatory manifestations:
Erythematous rash (n = 37, 70%)
Diffuse urticaria (n = 14, 26%) Varicelliform









Total population: 277 patients
Age, mean (range):
27 years (2–98)
‘‘Half of patients were male’’










Classification of skin lesions:
Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)
Other types of lesions (n = 41, 15%)
Description of vesicular:
Vesicles/varicella-like lesions = 21/41 (51%)


















Disseminated pattern in 18 pts (75%)—
Diffuse described as small papules,
vesicles, pustules with varying sizes
(7–8 mm in diameter), also
lesions appeared in different stages.
Localized pattern in 6 patients (25%)—
Localized pattern was monomorphic,
3–4 mm diameter, same stage
of evolution
Location of vesicular lesions:
Head (n = 4, 22.2%)
Anterior trunk (n = 17, 94.4%)
Posterior trunk (n = 12, 66.7%)
Arms (n = 8, 44.4%)
Legs (n = 10, 55.6%)
Palms/soles (n = 2, 11.1%)
Galvan
et al. (2020)11
Total population: 375 patients
153 males (40.8%),
222 females (59.2%)
Skin lesions: 375/375 (100%)
Vesicular: 34/375 (9%)
Age, mean (SD) = 45.6 years (20)
15 male (44%), 19 female (56%)
Laboratory confirmation
of SARS-CoV-2











Livedo or necrosis (6%)




Total population: 22 patients
Age, median: 60 years
16 male (72.7%) and
6 female (27.3)







pattern with predominance of papules
or vesicles in individual patients
Vesicular lesions:
Scattered (n = 16)
Diffuse (n = 6)
Truncal involvement (n = 22)
Limbs (n = 4)
Recalcati
et al. (2020)5
Total population: 88 patients
Age/gender—N/A





Erythematous rash (n = 14)
Widespread urticaria (n = 3)
Chicken pox-like vesicles (n = 1)
Trunk was the primary location
for all lesions.
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cases seen in 14 positive COVID-19 patients with
cutaneous manifestations.44 Finally, a case series of
five patients suffering from respiratory failure due
to severe COVID-19 infections had three of the
patients exhibiting purpuric skin rashes.53 Histo-
pathological examination involving one of these
patients with retiform purpura showed significant
interstitial and perivascular neutrophilia along
with prominent leukocytoclasia.53
Proposed pathogenesis for petechiae/purpura
skin lesions involves a ‘‘pauci-inflammatory
thrombogenic vasculopathy.’’ Immunohistochem-
istry performed by Magro et al. displayed exten-
sive deposition of complement components C5b-9
and C4d within the cutaneous microvasculature of
both lesional and nonlesional (normal appearing)
skin. These complement components could some-
times be seen colocalized with COVID-19 spike
glycoproteins.53 Due to the severity of COVID-19
cases seen with petechiae/purpura an alternate
etiology of the lesions could involve adverse der-
matological effects associated with potential
COVID-19 drugs. Cutaneous side effects of high-
dose IVIG treatments include petechiae among
many others. Purpura is an adverse skin effect of
the possible anti-COVID-19 agent camostat me-
sylate.20 Finally, a direct cutaneous manifestation
from SARS-CoV-2 could be a possibility consider-
ing petechiae are the result of other viral infec-
tions. Other significant hypotheses about the
potential causes of petechiae/purpura lesions
have been provided in Table 9.
Livedoid eruption lesions
Livedo reticularis (LR) is a transient or per-
sistent cutaneous manifestation that classically
presents with a reticular (net-like, lace-like)
pattern of reddish-blue to purple mottled discol-
orations (Fig. 7). This dermatosis is a conse-
quence of disturbed cutaneous vasculature
yielding diminished blood flow and deoxygenated
hemoglobin to the skin. Benign manifestations of
livedoid eruptions that primarily occur due to
physiological conditions (cutus marmorata) or
idiopathically are referred to as being LR. Live-
doid eruptions that occur secondary to patholog-
ical conditions are termed livedo racemosa
(LRC).54 LRC presents as a permanent manifes-
tation while exhibiting a more widespread ap-
pearance on the body and a broken/irregular
shape compared to LR.54
Livedoid eruptions appear to be one of the least
common cutaneous manifestations reported during
the COVID-19 pandemic (Table 6). In a study of
375 confirmed COVID-19 patients with cutaneous
manifestations, only 6% of them presented with
varying degrees of livedoid lesions and necrosis.11
Anatomical locations for these lesions include the
Figure 6. Examples of petechial/purpuric rash seen during the COVID-19 pandemic. (A) Purpuric rash thought to be associated with mild COVID-19 infections
according to Wollina et al. (B) Rash on patient’s chest is described as erythematous. Additional petechial lesions are exhibited on patient’s abdomen and arms.
(C) Purpuric lesions present on knees of patient. (D) Palpable purpuric lesions, resulting from subdermal hemorrhages, were distally located on lower
extremity of COVID-19 hospitalized patient. (E) Maculopapular purpuric exanthema presenting symmetrically on the trunk of a 59-year-old man with severe
respiratory failure due to COVID-19. (F) Purpuric eruption on the distal upper extremities of a 59-year-old man with severe COVID-19 infection. (G, H) ‘‘Skin
biopsy revealed a dermal perivascular neutrophilic infiltrate (H&E, 10 · ) with sparse leukocytoclasis, red blood cell extravasation, and fibrinoid necrosis (H&E,
40 · ).’’ Reproduced with permission from John Wiley and sons (A, H). The following original reports are credited: Wollina et al.43; Marzano et al.50; Rubio-Muniz
et al.14; Caputo et al.52
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123 male (58.6%), 87 female (41.4%)
Skin lesions: 52/210 (24%)
33 male (26.8%), 19 female (21.8%)
Petechiae/Purpura: 4/52 (7.7%)
SARS-CoV-2 PCR in total population,
PCR performed in 158 patients:
Positive: 88/158 (55.7%)
Negative: 70/158 (44.3%)




Classification from 52 patients
with skin lesions:
Erythematous scaly rash
(n = 17, 32.7%)
Maculopapular rash (n = 12, 23%)
Urticarial lesions (n = 7, 3.5%)
Petechial purpuric rash (n = 4, 7.7%)
Necrosis (n = 4, 7.7%)
Enanthema, aphthous stomatitis
(n = 3, 5.8%)
Vesicular rash (n = 3, 5.8%)
Pernio (n = 1, 1.9%)
Location of petechial lesions:
Petechiae located on distal
extremities (n = 3)
Generalized petechial purpuric
eruption (n = 1)
Bouaziz
et al. (2020)44
Total population: 14 patients
Age/gender N/A




SARS-CoV-2 PCR in 14 patients:
Positive: 14/14 (100%)
Inflammatory lesions = 7/14:
Exanthema (n = 4)
Chicken pox-like virus (n = 2)
Cold urticaria (n = 1)




Livedo (n = 1)
Non-necrotic purpura (n = 1)
Necrotic purpura (n = 1)
Chilblain appearance with Raynaud’s
phenomenon (n = 1)
Chilblain (n = 1)




Total population: 277 patients
Age, mean (range): 27 years (2–98)
‘‘Half of patients were male’’
Skin lesions: 277/277 (100%)
Petechial: 7/277 (3%):
Age, mean (range): 21 years (5–70)
5 male (71.4%), 2 female (28.6%)
SARS-CoV-2 PCR completed
in 34 (12%) patients:
Positive: 25/34 (73.5%)
Negative: 9/34 negative (26.5%)
Classification:
Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)
Other types of lesions (n = 41, 15%)
Location of petechial lesions:
Diffuse (n = 3, 43%)
Acral (n = 2, 29%)
Limbs (n = 2, 29%)
Docampo-Simon
et al. (2020)35
Total population: 58 patients
Age, median (range): 14 years
(3 months-85 yrs)
29 male (50%), 29 female (50%)
Skin lesions: 58/58 (100%)
Purpuric: 3/58 (5.17%)
SARS-CoV-2 PCR performed




Chilblain-like lesions (n = 42)
Purpuric (n = 3)
Maculopapular (n = 3)
Vesiculobullous (n = 3)
Eczematous (n = 3
Paronychia (n = 2)
Ulcer (n = 1)
Desquamation (n = 1)
Location of ALL lesions:
Hands (n = 9, 15.5%)
Feet (n = 36, 62.1%)
Hands and Feet
(n = 13, 22.4%)
Magro
et al. (2020)53
Total population: 5 patients
Skin lesions: 3/5 (60%)
1 male, age 32 years old
2 females, ages 40 and 66 years




Purpuric lesions (n = 3)
Description:
Retiform purpura (33.3%)
Dusky purpuric patches (33.3%)
Mildly purpuric reticulated
eruptions (33.3%)
Location of purpuric lesions:
Buttocks (retiform purpura)
Palms and soles (dusky
purpuric patches)





Total population: 34 patients
Age, mean (range): 54.5 years (31–66)
14 male (41%), 20 female (59%)
Skin lesions: 34/34 (100%)
Palpable purpura: 4/34 (11.8%)
Age, mean (range): 62 years (57–69)
1 male (25%), 3 female (75%)
SARS-CoV-2 PCR:
Positive PCR: 17/34 (50%)
Negative PCR: 9/34 (26%)
Radiological diagnosis:
Confirmed: 8/34 (23.5%), 4 with
negative PCR
Total confirmed: 25/34 (73.5%)
Patients with palpable purpura:
Positive RT-PCR: 2/4 (50%)
Radiological diagnosis: 1/4 (25%)
Suspected: 1/4 (25%)
Classification:
Maculopapular (n = 10)
Pseudo-chilblain (n = 9)
Targetoid lesions (n = 5)
Palpable purpura (n = 4 of which
2 cases are with vesicular lesions)
Acute urticaria (n = 3)
Vesicular (n = 2, these also have
palpable purpura)
Remaining 3 cases include livedo
reticularis, urticarial exanthem,
and prurigo lesions.
A figure displayed palpable
purpara lesions on the lower
extremities of a patient
suffering from COVID-19
pneumonia.
RT-PCR, reverse transcription polymerase chain reaction.
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trunk, flexor surface of forearms, dorsal hand, and
dorsal foot.11,44,55 These lesions occurred at the
same time as other Covid-19 symptoms and pri-
marily appeared in elderly patients with more se-
vere infections. Duration of this lesion was 9.4 days
on average. According to a Spanish case series, the
mortality rate among patients with livedoid lesions
was the highest of all cutaneous manifestations at
10%.11
While the molecular mechanisms of livedoid
eruptions are not yet known, a few theories
have been discussed. One of these theories is the
relationship of hypercoagulability to Covid-19
infections. A retrospective study of 183 patients
with Covid-19 showed that nonsurvivors of the
study had higher D-dimer and fibrin degradation
product levels, in addition to a longer prothrom-
bin time, suggesting that patients with severe
COVID-19, similar to those presenting with live-
doid lesions, are at a greater risk for coagulation
abnormalities.56 Manalo et al. hypothesize that
DIC and macrothromboses may be associated to
the production of LR in more severe cases of
infection. In less severe cases of COVID-19, mi-
crothrombi formation created by inflammatory
cytokines or ACE2 entry into cells may be impli-
cated in the production of LR.57 Other significant
hypotheses about the potential causes of livedoid
lesions have been provided in Table 9.
Multisystem inflammatory syndrome
in children
Throughout the pandemic, children have re-
mained relatively unscathed from severe COVID-19-
related complications. This remained true until late
April 2020, when multiple reports of critically ill
children exhibiting severe inflammatory syndrome
with Kawasaki disease-like features were first made
public in the United Kingdom.58 Verdoni et al. later
reported that within a short time span, they
had witnessed a 30-fold increased incidence of
Kawasaki-like disease primarily in children who
tested positive for antibodies against SARS-CoV-2.59
Since then, cases of this new and serious health
condition labeled as MIS-C have grown incremen-
tally throughout the world (Fig. 8). MIS-C is said to
exhibit overlapping features of Kawasaki disease
and toxic shock syndrome in a minute number of
children exposed to COVID-19.58 However, it is im-
portant to note that MIS-C also has a few noticeable
differences when compared to Kawasaki disease
such as an older onset (older children and adoles-
Figure 7. Examples of livedoid rash seen during the COVID-19 pandemic. (A) Livedoid lesions, often a product of vasculopathy, present on patient’s buttocks.
(B) Lesions affecting the patient’s lower extremities (thighs) are characterized as livedo racemose like. (C) Livedoid eruption present in an intubated patient
with severe systemic and pulmonary symptoms associated with COVID-19. Reproduced with permission from John Wiley and sons (A, B); Wolters Kluwer
Health, Inc. (C). The following original reports are credited: Galván Casas et al.52; Marzano et al.50; Gianotti et al.18
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Total population: 14 patients
Age/gender NR
Skin lesions: 14/14 (100%)
Livedo: 1/14 (7.1%)
SARS-CoV-2 PCR in 14 patients:
Positive: 14/14 (100%)
Inflammatory lesions = 7/14:
Exanthema (n = 4)
Chicken pox-like virus (n = 2)
Cold urticaria (n = 1)
Vascular lesions = 7/14:
Violaceous macules with ‘‘porcelain-like’’
appearance (n = 1)
Livedo (n = 1)
Non-necrotic purpura (n = 1)
Necrotic purpura (n = 1)
Chilblain appearance with Raynaud’s
phenomenon (n = 1)
Chilblain (n = 1)











Skin lesions: 6/6 (100%)
Livedo/necrosis: 3/6 (50%)
SARS-CoV-2 PCR: All negative





Red to violaceous macules and dusky
purpuric plaques scattered mid-
and distal parts of the toes; severely
affected digits with edematous,
superficial bullae and focal hemorrhagic
crust; petechial and purpuric macules
on heels, soles, and dorsolateral foot;
few cases with erythematous macule
around the distal nail folds; half the
cases with livedo reticularis of flexor
surface of forearms, dorsal hand,
and dorsal feet





Total population: 277 patients
Age, mean (range):
27 years (2–98)
‘‘Half of patients were male’’
Skin lesions: 277/277 (100%)
Livedo reticularis: 4/277 (1.4%)
SARS-CoV-2 PCR completed




Morbilliform lesions (n = 25, 9%)
Acral lesions (n = 142, 51%)
Vesicular lesions (n = 41, 15%)
Livedo reticularis (n = 4, 1%)
Urticarial lesions (n = 26, 9%)
Petechial lesions (n = 7, 3%)










Other—trunk, limbs, and face
Galvan
et al. (2020)11
Total population: 429 patients
54 patients excluded, 375 patients
in study,
153 males (40.8%), 222 females
(59.2%)
Skin lesions: 375/375 (100%)
Livedo/necrosis: 21/375 (6%)
Age, mean (SD): 63.1 years (17.3)
11 male (52.4%), 10 female (47.6%)
Laboratory confirmation
of SARS-CoV-2











Livedo or necrosis (6%)
Truncal or acral ischemia
Rubio-Muniz
et al. (2020)14
Total population: 34 patients
Age, mean (range):
54.5 years (31–66)
14 male (41%), 20 female (59%)
Skin lesions: 34/34 (100%)
Livedo: 1/34 (2.94%)
SARS-CoV-2 PCR:
Positive PCR: 17/34 (50%)
Negative PCR: 9/34 (26%)
Radiological diagnosis:
Confirmed: 8/34 (23.5%), 4 with
negative PCR
Total confirmed: 25/34 (73.5%)
Classification:
Maculopapular (n = 10)
Pseudo-chilblain (n = 9)
Targetoid lesions (n = 5)
Palpable purpura (n = 4, of which 2 cases
are with vesicular lesions)
Acute urticaria (n = 3)
Vesicular (n = 2, these also have palpable
purpura)
Remaining 3 cases include livedo reticularis,
urticarial exanthem, and prurigo lesions.
N/A
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cents), abdominal symptoms, and a greater number
of cases with heart conditions.60
Diagnostic criteria for Kawasaki disease involve
a diffuse polymorphic rash, including maculo-
papular, erythema multiforme like, or diffuse ery-
throderma.61 Similar erythematous polymorphic
rashes are predominantly seen in patients reported
to have MIS-C.59 Whittaker et al. reported a case
series in which 30 of the 58 patients diagnosed with
MIS-C had erythematous rashes, with one patient
having additional purpuric manifestations.62 A
retrospective chart review conducted by Miller
et al. likewise discovered rashes present in 31 out
of 44 patients; this was the third most common
symptom in patients with MIS-C after fever and
gastrointestinal symptoms.63 One study comprised
35 patients positive for MIS-C and described the
location of rash seen in 13 patients (37%) as being
variably distributed, including limbs, face, and
generalized.64 Many other studies found rash to be
common in MIS-C patients; however, detailed anal-
ysis on the type of rash, onset, and duration was not
mentioned59,65–73 (Table 7). Additional research is
needed to study and clarify the skin manifestations
of MIS-C and its association with COVID-19.
Etiology of Kawasaki disease is largely un-
known, although a genetic predisposition has been
established. Similarly, the molecular mechanisms
behind MIS-C’s cutaneous manifestations and their
relationship to COVID-19 are also unidentified.74
DISCUSSION
The COVID-19 pandemic, a consequence of the
recent emergence of SARS-CoV-2 in humans,
continues to spread rapidly resulting in an ongo-
ing global health crisis. Despite the daily emer-
gence of new data, much remains relatively
unknown in regards to COVID-19’s clinical char-
acteristics, including its cutaneous manifesta-
tions. As a novel strain of the Coronavirus family,
which is most commonly known for its respiratory
tract infections, SARS-CoV-2 has been associated
with many viral exanthems. Although a few re-
spiratory viruses have been associated with cu-
taneous manifestations in the past,47 these rashes
are uncharacteristic of the Coronavirus family.75
COVID-19’s cutaneous manifestations can be di-
vided into two categories, either inflammatory
exanthems or vascular lesions.7 Knowledge of the
changes in skin morphology related to COVID-19
may be instrumental in helping physicians diag-
nosis and treat future COVID-19 patients.
Patterns of COVID-19 exanthems include ma-
culopapular, urticarial, vesicular, and MIS-C rash.
Among these exanthems, maculopapular rashes
Figure 8. Examples of maculopapular rash seen in MIS-C patients during the COVID-19 pandemic. (A, B) Maculopapular/morbilliform rash, described as
polymorphous, present on 3-year old’s trunk and lower extremities. (C) Maculopapular rash present in a 12-year-old patient with Kawa-COVID-19. (D–G)
Maculopapular lesions present in a 12-year-old girl with MIS-C. (H) Skin rash present on 5-year-old patient with MIS-C. MIS-C, multisystem inflammatory
syndrome in children. Reproduced with permission from John Wiley and sons (A, B, H), BMJ Publishing Group Ltd. (C) and Wolters Kluwer Health, Inc. (D–G).
The following original reports are credited: Yozgat et al.72; Pouletty et al.67; Belhadjer et al.65; Bahrami et al.73
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Confirmed COVID-19 COVID-19 Cutaneous Manifestations
Belhadjer
et al. (2020)65
Total population: 35 patients
Age, median (range): 10 years (2–16)
18 male (51%), 17 female (49%)
Skin rash: 20/35 (57%)
Positive SARS-CoV-2 PCR: 14/35 (40%)
Positive serology: 30/35 (86%)
CT chest: typical for infection in 2 patients
Total confirmed = 31/35 (88.5%)
Classification:
Unspecified MIS-C rash (n = 19)
Description:




Total population: 17 patients
Age, median (range): 8 years (1.8–16)
8 male (47%), 9 female (53%)
Skin rash: 12/17 (71%)
Skin desquamation: 3/17 (18%)




Unspecified MIS-C rash (n = 12)
Grimaud
et al. (2020)68
Total population: 20 patients
Age, median (range): 10 year (2.9–15)
10 male (50%), 10 female (50%)
Skin rash: 10/20 (50%)
Positive SARS-CoV-2 PCR: 12/20 (60%)
Positive serology: 15/20 (75%)
Confirmed: 19/20 (95%)
1 patient with negative PCR and serology
however, chest CT chest typical for infection.
Classification:
Unspecified MIS-C rash (n = 10)
Hameed
et al. (2020)64
Total population: 35 patients
Age, median (IQR): 11 years (8)
(4/35 patients under the age of 5 years)
27 male (77%), 8 female (23%)
Skin rash: 13/35 (37%)
SARS-CoV-2 PCR: 35/35 negative
Serology performed in 30 patients:
27/30 positive (90%)
3/30 negative (10%)
Unspecified MIS-C rash (n = 13)
Kaushik
et al. (2020)71
Total population: 33 patients
Age, median (IQR): 10 years (6–13)
20 male (60.6%), 13 female (39.4%)
Skin rash: 14/33 (42%)
Positive SARS-CoV-2 PCR: 11/33 (33%)
Positive serology: 27/33 (81%)
RT-PCR and serology positive: 6 (18%)
Unspecified MIS-C rash (n = 14)
Miller
et al. (2020)63
Total population: 44 patients
Age, median (range): 7.3 years
(7 months–20 years) (SD 4.98)
20 male (45%), 24 female (55%)
Skin rash: 31/44 (70.5%)




Serology completed in 32 patients:
Positive: 31 (96.9%)
Inderterminate: 1 (3.1%)
Unspecified MIS-C rash (n = 44)
Pouletty
et al. (2020)67
Total population: 16 patients
Age, median (IQR): 10 years (4.7 to 12.5)
8 male (50%), 8 female (50%)
Skin rash: 13/16 (81%)
Positive SARS-CoV-2 PCR: 11/16 (69%)
Positive serology: 7/8 (87%)
Negative using both PCR and serology: 2
Classification:
Unspecified MIS-C rash (n = 13)
Description:
Diffuse skin rash (n = 13)
Maculopapular rash (n = 1)
Rash/edema of hands and feet (n = 11)
Riollano-Cruz
et al. (2020)70
Total population: 15 patients
Age, mean (range): 12 years (3–20)
11 male (73%), 4 female (27%)
Skin rash: 7/15 (47%)
Positive SARS-CoV-2 PCR: 9/15 (60%)
Positive serology: 15/15 (100%)
Total confirmed 15/15 (100%)
Classification:
Unspecified MIS-C rash (n = 7)
Toubiana
et al. (2020)66
Total population: 21 patients
Age, median (range): 7.9 years
(3.7–16.6)
9 male (43%), 12 female (57%)
Skin rash: 16/21 (76%)
Positive RT-PCR: 8/21 (38%)
Positive IgG serology: 19/21 (90.5%)
Total confirmed 19/21 (90.5%)
Classification:
Unspecified MIS-C rash (n = 16)
Description:
Polymorphous skin rash (n = 16)
Verdoni
et al. (2020)59
Total population: 10 patients
Age, mean (SD): 7.5 years (3.5)
7 male (70%), 3 female (30%)
Skin rash: 8/10 (80%)
Positive SARS-CoV-2 PCR: 2/10 (20%)
Positive serology: 8/10 (80%)
Classification:
Unspecified MIS-C rash (n = 8)
Description:
Polymorphous skin rash (n = 8)
Whittaker
et al. (2020)62
Total population: 58 patients
Age, median (IQR): 9 years (5.7–14)
25 male (43%), 33 female (57%)
Skin rash: 30/58 (52%)
Positive SARS-CoV-2 PCR: 15/58 (26%)
for respiratory PCR only
Positive IgG antibody: 40/46 (87%)
Any SARS-CoV2 PCR or IgG: 45/58 (78%)
Patients with erythematous rash:
Positive: 21/30 (70%)
Negative: 9/30 (30%)
Erythematous rash (n = 30)
Purpuric features (n = 1)
MIS-C, multisystem inflammatory syndrome in children.
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appear to be the most common followed by urti-
carial, vesicular, and MIS-C rashes. Maculopapu-
lar and urticarial exanthems are more commonly
seen in middle-aged to older patients and are typ-
ically associated with severe COVID-19 infections.
Rash onset of both varies between studies. Both are
reported to be unhelpful in diagnosis as the rash
can be due to possible drug-induced dermatological
adverse reactions. Onset of vesicular eruptions also
vary, while the majority are seen after the pre-
sentation of systemic symptoms, few cases have
noted onset prior to systemic symptoms. The rash
was noted frequently among middle-aged patients.
Of note, this type of exanthem is commonly seen
in other viral infections, such as varicella zoster and
herpes simplex. MIS-C is a novel and severe disease
seen in children; therefore, not much is known
concerning its clinical characteristics. Despite the
lack of information, published data show that skin
manifestations appear in a majority of MIS-C pa-
tients. There is also a possible correlation with Ka-
wasaki’s disease along with an association involving
immunoglobulins as a treatment modality.
Vascular lesions associated with COVID-19 are
characterized into pseudo-chilblain, petechiae/
purpura, or livedoid. Chilblain-like lesions are very
similar to pernio lesions that occur after exposure
to very cold temperatures; however, unlike pernio,
these lesions appear in warmer climates. These
lesions are commonly located on the fingers and
toes of younger patients and are associated with
less severe COVID-19 infections. Onset of pseudo-
chilblain lesions is typically after the onset of
COVID-19 systemic symptoms. Petechiae/purpura
lesions are more common in middle-aged patients.
These lesions have been associated with a greater
severity of COVID-19 infection. Studies involv-
ing these lesions have described their location
as being diffuse, acral, or on distal extremities/
limbs.15,16 Livedoid lesions are among the least
common skin manifestations seen during the
pandemic. They are primarily seen in elderly pa-
tients and have been correlated with particularly
severe COVID-19 infections.11
The pathophysiologic mechanisms behind
COVID-19’s skin manifestations are not well
known; however, many theories have been consid-
ered. Maculopapular and urticarial rashes are
believed to be due to an adverse reaction to phar-
maceutical COVID-19 drugs or overproduction of
cytokines triggered by hyperinflammation.12,20
Possible molecular mechanisms of chilblain-like
lesions are numerous, including ‘‘immune dysre-
gulation, vasculitis, vessel thrombosis, or neoan-
giogensis.44’’ Pathogenesis for petechial/purpuric
skin lesions involves pauci-inflammatory throm-
bogenic vasculopathy with extensive deposition of
complement components C5b-9 and C4d within the
cutaneous microvasculature. Alternative etiology
of these skin lesions could be adverse dermatolog-
ical side effects to medications used for COVID-19.
Livedoid’s molecular mechanisms are hypothe-
sized as being dependent on the severity of the
COVID-19 infection. In more severe infections, li-
vedoid eruptions are thought to be due to DIC and
macrothromboses. In less severe COVID-19 infec-
tions, these vascular lesions are assumed to be a
product of microthrombi formation created by in-
flammatory cytokines or ACE2 entry into cells.
Vesicular lesions are thought to result from ‘‘cyto-
kine storm’’ due to hyperactivity of the immune
system. Proposed etiology of MIS-C remains un-
known. Finally, it should also be noted that the
cutaneous manifestations seen during this pan-
demic might be a direct effect of the SARS-CoV-2
virus.
Although skin rashes as seen in SARS-CoV-2 are
unusual in comparison to other coronaviruses,
many respiratory viruses have been associated
with cutaneous manifestations (Table 8). Similar to
SARS-CoV-2, certain adenovirus serotypes can
present with maculopapular, vesicular, or petechial
exanthems.47 Exanthems due to influenza viruses
are extremely rare, seen in only 2–8% of cases and
present more frequently in children compared to
adults.47 Skin manifestations seen in influenza A
are petechial, macular, papular, maculopapular,
reticular, or purpuric patterns, while influenza B
exanthems are less common and include localized
or generalized morbilliform patterns.76
Human bocavirus rashes were primarily seen in
children and include maculopapular erythema,
macular erythema, and petechial exanthema.77,78
Nonpolio enteroviruses, such as echovirus and
coxsackie virus, are the leading cause of rashes in
children, especially during the summer and fall.47
Coxsackievirus causes hand-foot-mouth disease
(HFMD) and typically presents with diffuse ma-
culopapular or vesicular exanthems along with a
fever.47 In addition to HFMD, echoviruses can also
cause aseptic meningitis and are known to exhibit
macular, maculopapular, petechial, or vesicular
rashes.47,79 Nonpruritic, maculopapular, and
transient rashes were located on the trunk and
back of some children with human metapneumo-
virus infections.80 Exanthems described as ery-
thematous, maculopapular, and discrete were
found to be associated with rhinoviruses, respira-
tory syncytial virus, and parainfluenza viruses
(types 1–3).47,81
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Table 8. Comparative analysis of other respiratory viruses with cutaneous manifestations




1953 Person to person through respiratory
droplets, fecal-oral, and close contact.
Touching infected objects. (UpToDate)
Respiratory tract infections, including
pharyngitis, coryza, otitis media,
bronchiolitis, and pneumonia.
(UpToDate)
Maculopapular, vesicular, or petechial
exanthems. Primarily seen in children,
but sometimes in adults.
Coronaviridae (enveloped +ssRNA)
SARS-CoV75 2003 Person to person through respiratory
droplets and close contact.
Speculation of fecal-oral or airborne
spread. (UpToDate)
3–7 day prodrome with fever, malaise,
headache, and myalgias. Respiratory
phase begins with nonproductive cough
followed by dyspnea. Could lead to
respiratory failure. (UpToDate)
None reported
MERS-CoV75 2012 Person to person through respiratory
droplets and close contact.
Most common were severe pneumonia,
acute respiratory distress syndrome,
and acute kidney injury. (UpToDate)
None reported
SARS-CoV-2 2019 Person to person through respiratory
droplets and close contact. Touching
infected objects.
Fever, cough, myalgia, and pneumonia
when severe.
Maculopapular/morbilliform, vesicular,
urticarial, livedo/necrosis, MIS-C rash,
pseudo-chilblain, petechial.
Orthomyxoviridae (enveloped -ssRNA)
Influenza A76 1933 Person to person through respiratory
droplets and close contact. Touching
infected objects.
Fever, headache, myalgia, and malaise.
Respiratory tract symptoms include
nonproductive cough, sore throat, nasal
discharge, and pneumonia. (UpToDate)
Rash characterized as petechial,
macular, papular, maculopapular,
reticular, or purpuric. Could be
localized multifocal, generalized,
pruritic, and nonpruritic.
Influenza B76 1940 Person to person through respiratory
droplets and close contact. Touching
infected objects.
Fever, headache, myalgia, and malaise.
Respiratory tract symptoms include
nonproductive cough, sore throat, nasal
discharge, and pneumonia. (UpToDate)
Localized or generalized morbilliform





2005 Not much is known about the routes
of transmission. (PMID 18400798)
Cough, fever, rhinorrhea, asthma
exacerbation, bronchiolitis, acute
wheezing, and pneumonia. Primarily in
children.
Maculopapular erythematous rash,





Late 1950s Person to person primarily through
inhalation of large droplets or fomites.
(UpToDate)
Adults: Upper respiratory infections,
including fever, rhinorrhea, cough, and/or
sore throat. Other symptoms include acute
bronchitis and pneumonia.
Child: Croup, pneumonia, and bronchiolitis.
(UpToDate)
Rash observed in 6.5% of 398 HPIV-
infected children. Rash is
erythematous, maculopapular, and
discrete.
RSV47,81 1956 Person to person through respiratory
droplets and close contact. Touching
infected objects.
Infants and young children: lower respiratory
tract infections, including bronchiolitis
or pneumonia.
Older children and adults: upper respiratory
tract symptoms, including cough, coryza,
rhinorrhea, and conjunctivitis. Also, lower
respiratory tract disease. (UpToDate)
Rash more frequent in RSV-B patients






Late 1940s Predominantly through direct or indirect
oral contact with fecally shed virus.
Routes include contaminated water,
food, and fomites. (UpToDate)
Begins with low-grade fever and malaise
followed by hand-foot-mouth disease.




1950s Predominantly through direct or indirect
oral contact with fecally shed virus.
Routes include contaminated water,
food, and fomites. (UpToDate)
Can cause hand, foot, and mouth disease
in children. In adults, it can cause aseptic




Disseminated or localized vesicles.
Rhinovirus47,81 1956 Person to person through respiratory
droplets and close contact. Touching
infected objects.
Children: Cough, nasal discharge, and
obstruction more frequently than adults.
May initially have a fever.
Adults: Nasal discharge, nasal obstruction,
cough, and/or a sore or scratchy throat.
No fever. (UpToDate)





2001 Person to person through respiratory
droplets and close contact. Touching
infected objects. (CDC)
Cough, fever, nasal congestion, and
shortness of breath. Can progress to
bronchitis and pneumonia. (CDC)
Nonpruritic, maculopapular, and
transient rash.
CDC, Centers for Disease Control and Prevention; MERS-CoV, Middle East respiratory syndrome coronavirus; RSV, respiratory syncytial virus.
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So far, we have discussed about the virus-
induced or drug-induced skin lesions seen in pa-
tients infected with SARS-CoV-2. However, this
pandemic has silently resulted in additional cuta-
neous complications, although indirectly through
the use of PPE (Fig. 9). These complications include
pressure injury, contact dermatitis, urticaria, skin
dryness, and aggravation of existing skin dis-
eases.31 PPE refers to wearable personal items used
to protect against accidental injuries and occupa-
tional hazards.82 Due to the possible asymptomatic
transmission of SARS-CoV-2 among unknowing
individuals, the widespread use of PPE has become
mandatory for the reduction of infection rates and
prevention of viral spread, especially among front-
line health care personnel. These individuals must
protect both themselves from occupational hazards
and their most vulnerable patients by wearing
multiple types of PPE equipment, including gog-
gles/disposable face shields, N95 respirator masks,
protective gowns, and latex gloves.
Despite the overall benefits of wearing PPE,
their frequent and prolonged use among health
care personnel during the COVID-19 pandemic
have been associated with various adverse skin
injuries83 (Fig. 9). PPE-related skin complications
are of serious concern since broken cutaneous bar-
riers can create an opening for potential COVID-19
infections and increase contamination by inadver-
tently spreading the virus.84 In the following sec-
tion, we will discuss the causes and characteristics
of skin damage caused by the use of various types of
PPE, and introduce the possible measures for skin
protection and treatment strategies.
Incidences of PPE-associated skin rashes
in COVID-19 pandemic
A cross-sectional study from China reported the
overall prevalence of skin injuries instigated by PPE
use in medical personnel to be 42.8% among 4,306
surveyed participants. Analysis of the survey con-
ducted by Jiang et al. discovered three main types of
skin injuries. These were device-related pressure
ulcers (DRPU, now known as pressure injuries),
moisture-associated skin damage, and skin tears.83
Multivariate analysis of risk factors related to PPE-
induced skin injuries revealed higher prevalence
among males, doctors, participants wearing grade 3
PPE opposed as grade 2 PPE, those with daily
wearing times greater than 4 hours, age older than
35 years, and finally those who reported heavy
sweating.83
Another quantitative study out of China surveyed
61 health care workers regularly using PPE (N95
mask, latex gloves, and protective clothing). Adverse
skin reactions were discovered in 95.1% of N95 mask
users, the most majority of which being nasal bridge
scarring followed by facial itching and skin damage.
Around 88.5% of health care workers reported cu-
taneous complications due to latex gloves. The most
common skin reactions by these gloves were dry skin
and itching followed by rash and chapped skin. Fi-
nally, only 67% of the health care workers reported
adverse skin reactions due to protective clothing, the
most frequent being dry skin and itching.85
Of the cutaneous complications caused by
PPE, DRPU/pressure injuries are the most note-
worthy. Pressure ulcer/injury is defined by the
National Pressure Injury Advisory Panel (NPIAP)
as ‘‘localized damage to the skin and underlying
soft tissue usually over a bony prominence or re-
lated to a medical or other device.’’ Before the
COVID-19 pandemic, DRPU were primarily seen
in patients who were critically ill; however, this
pandemic has introduced DRPU as a novel com-
plication resulting in facial injuries among health
care personnel wearing PPE.86–88 The PPE devices
used among medical staff inducing DRPU were
Table 9. Potential causes of each dermatological findings
Dermatologic Finding Potential Causes
Maculopapular rash Viral exanthem, Scarlet fever, measles, rubella, medication reaction, secondary syphilis, heat rash, leukemia, graft-versus-host disease
Urticaria Allergic reaction, anaphylaxis, angioedema, autoimmune disease (e.g., systemic lupus erythematosus), hypereosinophilia, chronic urticaria,
malignancy
Vesicular Varicella zoster (i.e., chicken pox), herpes zoster (i.e., shingles), herpes simplex, Rhus dermatitis (e.g., poison ivy, poison oak, and poison
sumac), pemphigoid
Petechiae/purpura Thrombocytopenia, systemic lupus erythematosus, leukemia, DIC, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura,
vasculitis, vitamin C deficiency
Chilblains Raynaud’s phenomenon, systemic lupus erythematosus, systemic sclerosis, Buerger’s disease
Livedo racemosa Antiphospholipid antibody syndrome, Sneddon syndrome, cryoglobulinemia, multiple myeloma, DIC, hemolytic uremic syndrome, deep
venous thrombosis, systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, Sjogren’s syndrome, multiple sclerosis,
Parkinson’s disease, cancer (e.g., renal cell cancer, breast cancer, lymphoma, and leukemia)
Distal ischemia/necrosis Arterial ischemia, DIC, Buerger’s disease
Reproduced with permission from Elsevier LTD. The following original report is credited: Gottlieb et al.97
DIC, disseminated intravascular coagulation.
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N95 respirators, goggles, and protective masks.
PPE-induced DRPU in medical staff had an overall
prevalence of 30.03%, the highest among PPE-
induced skin injuries. For context, a systematic
review conducted in 2019 estimated the pooled
prevalence of non-PPE-acquired DRPU in adult
patients to be only 11%, a number significantly
lower compared to DRPU in medical personnel
during COVID-19.89 The majority of PPE-induced
DRPU were located on the nasal bridge and cheeks
(59.65%); lesser known locations included the
auricle, forehead, zygoma, mandible, and eyebrow
arch.87 Non-PPE-acquired DRPU locations inclu-
ded head, face, ears, feet, neck, sacrum, and but-
tocks.89 Around 98.84% of DRPU reported in the
medical staff belonged to Stage 1 and Stage 2 of
pressure ulcer categories. Risk factors for PPE-
induced DRPU were similar to those seen in overall
PPE-induced skin injuries; however, age was ex-
cluded as a significant risk factor.87
As mentioned earlier, the PPE primarily re-
sponsible for DRPU among the medical staff in
China included N95 respirators, goggles, and pro-
tective masks.87 Etiology of PPE-induced DRPUs is
thought to be very similar to etiology of DRPUs
from continuous positive airway pressure masks,
used for sleep apnea. The proposed mechanism
triggering pressure ulcers begins with prolonged
use of medical face masks and protective goggles,
resulting in facial skin indentation or damage.
Movement of facial muscles can inflict frictional
damage of the skin caused by tightening of PPE
straps and continuous movement of PPE over the
skin. This frictional damage can be increased by
perspiration of the medical personnel, eventually
leading to the shearing of skin and subdermal tis-
sues. In addition, the skin’s tolerance to mechani-
cal stress is weakened by increasing humidity at
the PPE-skin boundary. As a consequence of these
two unfavorable effects to the skin, tissue and cell
Figure 9. Examples of personal protective equipment-induced pressure ulcers seen during the COVID-19 pandemic. (A) Example of N95 respirator mask used
by health care professionals. (B) Pressure sore, caused by an N95 mask, located on the nasal bridge. (C) Possible preventable method includes the application
of benzalkonium chloride bridge before wearing mask. (D) Device-related pressure injury present on forehead of medical staff member fighting COVID-19 in
China. (E) Device-related pressure injuries and impressions on face of health care personnel. (F) Device-related pressure injury located on the neck.
Reproduced with permission from John Wiley and sons (A–C); Mary Ann Liebert, Inc. (D–F). The following original reports are credited: Yin91; Jiang et al.83
CUTANEOUS MANIFESTATIONS OF COVID-19 75
deformation can occur, potentially leading to cell
death if the deformation is sustained. Cell death
can initiate a damaging cycle of DRPU involving
inflammation, edema, interstitial pressure, ische-
mia, and tissue death.86 However, this cycle is an
unlikely outcome for PPE-induced DRPU due to
health care personnel being able to respond when
they sense any uncomfortable feeling.86
Treatment and management for PPE-induced
pressure ulcers
Treatment strategies vary among studies due
to the low number of cases reported. Lam et al.
reported a case series of five health care workers
presenting with nasal bridge pressure ulcers as-
sociated with N95 respirators.88 In all cases, the
N95 respirator remained on for an average of 5 h
each time the mask was applied. Four of these
cases were categorized as grade 1 pressure ulcers
and treated with Duoderm Extra Thin dressings
(hydrocolloid dressings), while one case was cat-
egorized as a grade 3 pressure ulcer and treated
with BETAplast.88 Thin hydrocolloid dressing
was also used as treatment in a case report of a
nurse presenting with a grade 2 pressure ulcer on
the nasal bridge. This case was also associated
with an N95 respirator mask.90 One study pro-
posed an improved treatment option for health
care personnel involving the addition of a ben-
zalkonium chloride patch to the pressure ulcer
before using hydrocolloid dressing and applying
the N95 mask. Reasoning behind this method in-
cluded protection of the existing pressure ulcer,
while preventing additional severity of the ulcer
when the patch was removed.91
Other treatment recommendations for PPE-
induced ulcers included wet dressing to promote
wound convergence, silver ion dressings to prevent
infection and secondary damage by frequent
dressing replacements, and epidermal growth fac-
tor/fibroblast growth factor to stimulate cell pro-
liferation and expedite wound healing.82
Possible complications arising from PPE-
induced ulcers could involve an introduction to
new infections and a breach of PPE protocol
leading to increased contamination. Interestingly,
the introduction of viral infections other than
COVID-19 or bacterial infections could lead to
cutaneous manifestations of their own, mimicking
those associated with COVID-19. Due to these
complications, prevention of PPE-induced pres-
sure ulcers is paramount. One of the preventative
methods discussed include proper PPE training;
this could reinforce the proper use of an N95 res-
pirator and discuss problems associated with ex-
tremely tight N95 mask securement.88 Other
preventative measures include the relief of pres-
sure buildup in N95 masks every 2 h and the ad-
dition of prophylactic barrier creams at least
30 min before applying the respirator mask.88 Fi-
nally, wearing a properly fitted mask, correct
goggle use, the application of moistures/gels, and
management of skin indentations could help pro-
tect one from a pressure injury.31
There are few limitations of this systematic
review. One of them being the large number of
suspected, but unverified COVID-19 patients due
to lack of testing or faulty tests. Also, studies over
the dermatologic side effects of medications are
absent. In addition, statistical analysis of the re-
sults is lacking due to the vast heterogeneity of
cutaneous manifestations, rash onset, duration,
and associated symptoms. The primary literature
articles included in this study were mainly from
France, Spain, Italy, and the United Kingdom.
Because a majority of articles originate from
Europe, this can present with its own limitations
in providing a diverse population/methodology.
Finally, some literature reviews concerning the
cutaneous manifestations were unable to be
translated to English; this may have also inter-
fered with data collection. Careful documentation
and examination by physicians experienced with
cutaneous manifestations are needed for im-





As the number of articles written about COVID-
19’s cutaneous manifestations increase daily, the
same cannot be said for possible treatments op-
tions. During primary literature review, most
Innovation: COVID-19 is an emergent dis-
ease, of which there is a clear void in under-
standing. Current actions are based on scientific
information as they emerge. Comprehensive
understanding of COVID-19 requires critical
examination of all manifestations as evident in
patients. A growing body of scientific evidence
points toward consistent skin pathologies in
COVID-19-affected patients. This article offers
a critical review of the current literature on
COVID-19 cutaneous manifestations. It also
addresses the risk of PPE-associated ulcer in
health care providers managing COVID-19.
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articles were geared toward the classifi-
cation, histology, and descriptions of the
cutaneous manifestations as well as ex-
planations of possible etiologies. Many
reports, including Galvin et al., reported
the use of proposed medications for the
treatment of COVID-19 itself: hydroxy-
chloroquine, NSAIDs, lopinavir/ritona-
vir, tocilizumab, azithromycin, and
systemic corticosteroids.11 As mentioned,
these treatment options were not used for
the rash, but many did note skin-
associated side effects. For example,
Sharma et al. reported common adverse
reactions of pruritus, urticaria, and ery-
thema multiforme with the use of hydro-
xychloroquine.92 Some of these adverse
cutaneous manifestations fall within the
abovementioned COVID-19 skin manifestations.
However, most of the discussed cutaneous mani-
festations of COVID-19 have been shown to be self-
resolving.93 De Giorgi et al. reported spontaneous
resolution of inflammatory cutaneous lesions, in-
cluding vesicular, petechial, and maculopapular
lesions.17 However, Reymundo et al. reported use
of systemic corticosteroids in six of seven patients
in the retrospective study looking into the presence
of maculopapular rash.13 Cordoro et al. reported
conservative care for patients with livedo-like le-
sions.55 Few studies also reported spontaneous
resolution for chilblain lesions.37,39 Mastrolonardo
et al. proposed the use of topical corticosteroids and
antibiotics for chilblains, but only as a means to
allow a faster recovery time otherwise the lesions
can self-heal.94 In the review article by Algaadi, the
author noted treatment for urticaria was chal-
lenging as there are many triggers that can lead to
this type of rash from simple allergic reaction to
viral to medication induced. In this review, treat-
ment involved the use of antihistamines with or
without steroid use.95 Majority of articles covering
multisystem inflammatory syndrome (Kawashi-
like rash) reported use of IVIGs.65,68,69,96 The exact
effects of these treatments on COVID-19 skin
manifestations are unclear and need further in-
vestigation.
SUMMARY
In conclusion, knowledge of COVID-19 cuta-
neous manifestations may be vital to early diag-
nosis and lead to possible better prognosis in
COVID-19 patients. This systematic review pro-
vides a detailed analysis of the primary skin
complications associated with COVID-19 and
their plausible underlying molecular mecha-
nisms. Furthermore, the importance and patho-
genesis of PPE-induced pressure ulcers are
provided, in addition to their possible treatments.
Further research concerning COVID-19’s cuta-
neous manifestations is very much needed for a
complete analysis of COVID-19.
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Abbreviations and Acronyms
ACE2 ¼ angiotensin-converting enzyme 2
CDC ¼ Centers for Disease Control and
Prevention
COVID-19 ¼ Coronavirus Disease 2019
DIC ¼ disseminated intravascular
coagulation
DRPU ¼ device-related pressure ulcer
H&E stain ¼ hematoxylin and eosin stain
HFMD ¼ hand-foot-mouth disease
IgA ¼ immunoglobulin A
IgG ¼ immunoglobulin G
IgM ¼ immunoglobulin M
IQR ¼ interquartile range
IVIG ¼ intravenous immunoglobulin
LR ¼ livedo reticularis
LRC ¼ livedo racemosa
MERS-CoV ¼ Middle East respiratory
syndrome coronavirus
MIS-C ¼ multisystem inflammatory
syndrome in children
N/A ¼ not available
NPIAP ¼ National Pressure Injury
Advisory Panel
NR ¼ not reported
NSAIDs ¼ nonsteroidal anti-inflammatory
drugs
PPE ¼ personal protective equipment
PRISMA ¼ Preferred Reporting Items
for Systematic Reviews
and Meta-Analyses
RSV ¼ respiratory syncytial virus
RT-PCR ¼ reverse transcription polymerase
chain reaction
SARS-CoV ¼ severe acute respiratory
syndrome coronavirus
SARS-CoV-2 ¼ severe acute respiratory
syndrome coronavirus 2
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